Drugs Made In America Acquisition II Corp. (DMII)
Market Open
11 Sep, 14:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
10. 18
+0.01
+0.0924%
$
647.83M Market Cap
- P/E Ratio
- Div Yield
3 Volume
- Eps
$ 10.17
Previous Close Want to track DMII and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Drugs Made In America Acquisition II Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| IH Isaac Haas Hbk Investments LP | 500,000 | $4.95M | $5.07M | $115,000 | 2.32% |
 Daniel L. Lippincott Karpus Management Inc. | 2.79M | $27.81M | $28.24M | $428,973.19 | 1.54% |
| SK Steven Katznelson Radcliffe Capital Management LP | 575,721 | $5.7M | $5.83M | $132,408.14 | 2.32% |
| BO Brian Oliveira Clear Street Group Inc. | 224,879 | $2.26M | $2.29M | $27,191.63 | 1.2% |
| MCS Mercuria Capital Strategies LLC Mercuria Capital Strategies LLC | 750,000 | $7.48M | $7.63M | $150,000 | 2.01% |
| AAS ABC Arbitrage SA ABC Arbitrage SA | 35,000 | $346,500 | $355,950 | $9,450 | 2.73% |
 Mikhail Shilshtut Limestone Investment Advisors LP | 151,000 | $1.52M | $1.54M | $17,681 | 1.16% |
